Depression
Conditions
Keywords
Depression, depressed, overweight, obese
Brief summary
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
Interventions
DRUGnaltrexone SR 32 mg/ bupropion SR 360 mg daily
All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks. During the study, subjects will receive ancillary therapy including advice on diet and exercise
Sponsors
Orexigen Therapeutics, Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Female and male subjects must be 18 to 65 years of age; * Have body mass index (BMI) greater or equal to 27 and less than or to equal 43kg/m2; * Meet criteria for major depression * Women of child-bearing potential, must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug; * Able to comply with all required study procedures and schedule; * Able to speak and read English; * Willing and able to give written informed consent
Exclusion criteria
* Obesity of known endocrine origin * Serious medical condition * History of drug or alcohol abuse or dependence * Use of excluded concomitant medications * History of surgical or device (e.g. gastric banding) intervention for obesity; * History or predisposition to seizures * Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug; * Planned surgical procedure that can impact the conduct of the study; * Use of investigational drug, device or procedure within 30 days prior to Screening; * Participation in any previous clinical trial conducted by Orexigen Therapeutics; * Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the change in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale (MADRS) total score at 12 weeks | 12 Weeks |
Secondary
| Measure | Time frame |
|---|---|
| To assess the percentage change from baseline in total body weight at 12 and 24 weeks. | 12 and 24 weeks |
Countries
United States
Outcome results
None listed